Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020235587 - TANDOSPIRONE DERIVATIVE

Publication Number WO/2020/235587
Publication Date 26.11.2020
International Application No. PCT/JP2020/019911
International Filing Date 20.05.2020
IPC
C07D 209/76 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
209Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
56Ring systems containing three or more rings
58- or -condensed
724,7-Endo-alkylene-iso-indoles
76with oxygen atoms in positions 1 and 3
A61K 31/496 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61P 25/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
A61P 25/18 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
CPC
A61K 31/496
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61P 25/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
A61P 25/18
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
C07D 209/76
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
209Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
56Ring systems containing three or more rings
58[b]- or [c]-condensed
724,7-Endo-alkylene-iso-indoles
76with oxygen atoms in positions 1 and 3
Applicants
  • 国立大学法人富山大学 NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA [JP]/[JP]
  • 学校法人金沢医科大学 KANAZAWA MEDICAL UNIVERSITY [JP]/[JP]
Inventors
  • 近藤 隆 KONDO Takashi
  • 阿部 仁 ABE Hitoshi
  • 倉知 正佳 KURACHI Masayoshi
  • 鈴木 道雄 SUZUKI Michio
  • 上原 隆 UEHARA Takashi
Agents
  • 長谷川 芳樹 HASEGAWA Yoshiki
  • 黒木 義樹 KUROKI Yoshiki
Priority Data
2019-09535921.05.2019JP
Publication Language Japanese (JA)
Filing Language Japanese (JA)
Designated States
Title
(EN) TANDOSPIRONE DERIVATIVE
(FR) DÉRIVÉ DE TANDOSPIRONE
(JA) タンドスピロン誘導体
Abstract
(EN)
A compound represented by formula (1) or a pharmaceutically acceptable salt thereof can be used as an active ingredient of a drug for central nervous system diseases or as a candidate compound for a precursor of said active ingredient. In formula (1), R1, R2, and R3 each independently represent a substance selected from the group consisting of a hydrogen atom, a hydroxy group, and an alkoxy group having 1-6 carbon atoms, and at least one of R1, R2, and R3 is a hydroxy group.
(FR)
La présente invention concerne un composé répondant à la formule (1) ou un sel pharmaceutiquement acceptable de celui-ci qui peut être utilisé en tant que principe actif d'un médicament pour des maladies du système nerveux central ou en tant que composé candidat pour un précurseur dudit principe actif. Dans la formule (1), R1, R2 et R3 représentent chacun indépendamment une substance choisie dans le groupe constitué par un atome d'hydrogène, un groupe hydroxy et un groupe alcoxy ayant de 1 à 6 atomes de carbone, et au moins l'un de R1, R2 et R3 représente un groupe hydroxy.
(JA)
下記式(1)で示される化合物又はその薬剤学的に許容できる塩は、中枢神経系疾患に対する薬剤の有効成分又はその前駆体の候補化合物となり得る。(式(1)中、R、R及びRは、それぞれ独立に、水素原子、ヒドロキシ基及び炭素数1~6のアルコキシ基からなる群から選択される基であり、R、R及びRのうちの少なくとも1つがヒドロキシ基である。)
Latest bibliographic data on file with the International Bureau